The European Medicines Agency’s advisory group CHMP has adopted a positive opinion backing the use of Eli Lilly’s (NYSE:LLY) Olumiant (baricitinib) for the treatment of moderate-to-severe atopic dermatitis in adults.

Olumiant is currently approved in Europe for moderate-to-severe rheumatoid arthritis.

A final decision from the European Commission usually takes ~60 days.


Source link